Pfizer closure a blow to science and growth confidence

Whilst Pfizer are saying that their closure of their Kent-based research site is due to internal changes in priorities it highlights both fundamental changes in the approach to drug research and development (R&D) and the urgent need for the UK government to know how to keep companies in the UK.

In order to build confidence in the UK, questions we need to be acting on the answers to as soon as possible include:

  • How quickly can we implement Sir Michael Rawlins’ report to encourage growth clinical trials in the UK?
  • We are still one of the lowest spenders on medicines of the OECD nations and our spend has been falling since 1994 according to their data – why aren’t we doing more to encourage the use of new drugs?
  • What is being done to encourage pupils to study science at A level and beyond to ensure an adequate workforce?
  • What are the barriers to universities developing new chemical entities and forming SMEs to commercialize them and enable re-investment?
  • Has anyone done the work on the longer term costs of research moving East? Costs will rise in India and China over time. Is there a period over which we can predict we should offer more incentives in the UK, knowing that eventually what we can offer here will be overall better value than can be found in the East?
  • Drug R&D is hugely expensive and risky and companies say that the UK is one of the most expensive countries in which to undertake it. Why – and what can we change?

No doubt the Budget will be seeking to stimulate growth, but that is 7 weeks away. Unequivocal, public decisions need to be taken now based on what we already know to ensure we retain, attract and develop our pharmaceutical base in the UK.

About Julia Manning

Julia is a social pioneer, writer and campaigner. She studied visual science at City University and became a member of the College of Optometrists in 1991, later specialising in visual impairment and diabetes. During her career in optometry, she lectured at City University, was a visiting clinician at the Royal Free Hospital and worked with Primary Care Trusts. She ran a domiciliary practice across south London and was a Director of the UK Institute of Optometry. Julia formed 20/20Health in 2006. Becoming an expert in digital health solutions, she led on the NHS–USA Veterans’ Health Digital Health Exchange Programme and was co-founder of the Health Tech and You Awards with Axa PPP and the Design Museum. Her research interests are now in harnessing digital to improve personal health, and she is a PhD candidate in Human Computer Interaction (HCI) at UCL. She is also dedicated to creating a sustainable Whole School Wellbeing Community model for schools that builds relationships, discovers assets and develops life skills. She is a member of the Royal Society of Medicine’s Digital Health Council. Julia has shared 2020health's research widely in the media (BBC News, ITV, Channel 5 News, BBC 1′s The Big Questions & Victoria Derbyshire, BBC Radio 4 Today, PM and Woman's Hour, LBC) and has taken part in debates and contributed to BBC’s Newsnight, Panorama, You and Yours and ITV’s The Week.
This entry was posted in Drugs, Pharma and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s